High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma
about
Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastomaBET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor ModelsMolecular pathogenesis of peripheral neuroblastic tumorsIdentification of cytotoxic drugs that selectively target tumor cells with MYC overexpressionA p53 drug response signature identifies prognostic genes in high-risk neuroblastomaInhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiationHOXD-AS1 is a novel lncRNA encoded in HOXD cluster and a marker of neuroblastoma progression revealed via integrative analysis of noncoding transcriptomeThe notch and TGF-β signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma.Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcomeCancer cell differentiation heterogeneity and aggressive behavior in solid tumors.RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaN-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53.The landscape of candidate driver genes differs between male and female breast cancer.Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells.Neuroblastoma: molecular pathogenesis and therapy.Targeting focal adhesion kinase in neuroblastoma.A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.HIF2A and IGF2 expression correlates in human neuroblastoma cells and normal immature sympathetic neuroblasts.An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition.The genetic landscape of high-risk neuroblastoma.CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.N-Myc knockdown and apigenin treatment controlled growth of malignant neuroblastoma cells having N-Myc amplification.HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells.Molecular characterization and classification of neuroblastoma.Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.Molecular signatures of antibody responses derived from a systems biology study of five human vaccinesCharacterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.G-quadruplexes as potential therapeutic targets for embryonal tumors.snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis.Gene therapy as a potential tool for treating neuroblastoma-a focused review.Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastomaDeubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells.Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.
P2860
Q26770306-7F6A5F15-0C64-424F-AE03-0476D56B9B78Q27679878-25DCC101-4D7A-4B53-BEE3-7072B08022A6Q28271405-EEE19E2A-4B94-4AD0-B41D-765136BE5A23Q28478132-031BA960-0E2B-4D8A-8432-0EE95D2F465FQ28537647-9493362C-DCEB-4E5F-9E03-96F23FA806BDQ28542016-09D58AB6-BD25-423A-AFB3-3280F0F081E1Q28652372-D5410845-7BD2-4012-AD68-4CC1B8763E93Q33986101-28D26BCA-EA32-474A-805B-F65C4785B830Q34247959-491393A5-B955-4716-953E-833F12403C80Q34257652-F147499C-87E7-4D7C-A805-0DE931546B47Q34602599-D686FB04-9C78-4EC1-8FB8-D7FF995B56B4Q35013089-E56214C6-1814-41A8-B233-2D8A84FFEE5BQ35032523-545EF836-4875-49CA-8EE9-2CA0AC4110C9Q35248327-C35C0776-762C-42ED-A288-3B12D72F2350Q35564199-78CC19B7-836E-4FB6-BBE5-B9392BFEF085Q35576162-AFF6B932-8669-42C5-802A-7751B0AA41D1Q35804064-FBF4F677-2C7F-410A-BEF5-606A1FA995CFQ36021061-0BD66BE9-014C-4D45-A36E-9729AE563D2BQ36437048-5ECD8442-B5BB-446C-A30D-BF327BFB9716Q36437713-F5B233B0-902F-4CB8-9E2B-802448AF2663Q36535291-D890FE30-88A5-4F23-A786-001DA9414779Q36670909-D3624E21-52A9-441E-A153-BED8B7EF82EAQ36911240-3A50DD04-059A-4D58-971D-A6C380AA6EFFQ36924454-D45970F3-8064-4176-A0D4-1BC8DF375857Q36929803-A77615A2-F995-4C16-BB32-C66204F19A63Q37040833-35A416F9-C3AF-4CB3-A603-72E671FF452FQ37247072-F9017C11-2405-44F4-8BE2-37ACA6FD9994Q37349993-9ECF2D83-E9A5-4C18-A1E8-F6F32239400CQ37515355-11E07E2D-2548-41A1-A43F-74FD31F9832DQ37605450-CAE4564F-32E2-4CEE-ACF5-1E92029E589FQ37625332-143A2DC9-BC70-4263-9FEE-345ADCEE21B3Q37688783-00279961-AAD0-4859-8A0F-5900B2C41AFDQ37940719-E9E93760-510F-470C-B359-1E4439EAD09FQ38154988-36D60C77-F64A-4E05-9C08-CFCA9C6B27FDQ38487500-B790BE7C-7DC9-4C6F-BECF-E41A92B6FB58Q38808728-F0C7200C-949F-4D64-9ADA-D9C3F5201177Q38817378-3B53BF1B-A2FC-4D68-A2CC-DC8F86E7C574Q38987154-F094B0E3-C367-4624-964F-95A18EFAD820Q39016943-96999DCF-0235-4DF4-A95B-B672E2586069Q39067047-F4C52FF8-7888-4068-AA02-1B06736506A8
P2860
High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
High Myc pathway activity and ...... poor outcome in neuroblastoma
@en
type
label
High Myc pathway activity and ...... poor outcome in neuroblastoma
@en
prefLabel
High Myc pathway activity and ...... poor outcome in neuroblastoma
@en
P2093
P2860
P356
P1476
High Myc pathway activity and ...... poor outcome in neuroblastoma
@en
P2093
Erik Fredlund
John M Maris
Sven Påhlman
P2860
P304
14094-14099
P356
10.1073/PNAS.0804455105
P407
P577
2008-09-09T00:00:00Z